Cargando…

Spacing out dual checkpoint inhibition improves antigen-specific T cell manufacture

Detalles Bibliográficos
Autores principales:	Wang, Hanmin, Wang, Leo D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772500/ https://www.ncbi.nlm.nih.gov/pubmed/36588822 http://dx.doi.org/10.1016/j.omtm.2022.11.007

Ejemplares similares

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
por: Barth, Stefan, et al.
Publicado: (2022)

Commentary: Squamous cell carcinoma of the esophagus: Another target for checkpoint inhibition
por: Whyte, Richard I.
Publicado: (2022)

Management of hepatitis B in the era of checkpoint inhibition
por: Dutcher, Janice
Publicado: (2020)

Resistance to systemic immune checkpoint inhibition in the peritoneal niche
por: Chia, Daryl Kai Ann, et al.
Publicado: (2022)

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
por: Symeonides, Stefan N., et al.
Publicado: (2017)

Building malaria out: improving health in the home
por: Tusting, Lucy S., et al.
Publicado: (2016)

Commentary: Help a sister out: Dual cannulation strategy for neonatal heart surgery in a conjoined twin
por: Overbey, Douglas M., et al.
Publicado: (2020)

Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?
por: Jalalizadeh, Mehrsa, et al.
Publicado: (2023)

Running on a treadmill: dynamic inhibition of APC/C by the spindle checkpoint
por: Díaz-Martínez, Laura A, et al.
Publicado: (2007)

Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase
por: Xu, Yanying, et al.
Publicado: (2017)

Point-of-care cell therapy manufacturing; it’s not for everyone
por: Stroncek, David F., et al.
Publicado: (2022)

Sphingomyelin is a prospective metabolic immune checkpoint for natural killer cells
por: Ma, Hongdi, et al.
Publicado: (2023)

Immunogenic cell stress and injury versus immunogenic cell death: implications for improving cancer treatment with immune checkpoint blockade
por: Sriram, Ganapathy, et al.
Publicado: (2022)

National initiatives to improve outcomes from out-of-hospital cardiac arrest in England
por: Perkins, Gavin D, et al.
Publicado: (2016)

Challenges to the development of antigen-specific breast cancer vaccines
por: Scanlan, Matthew J, et al.
Publicado: (2001)

Prostate-specific antigen-based screening: controversy and guidelines
por: Kim, Eric H, et al.
Publicado: (2015)

Antigen-specific immunotherapy for MOG antibody-associated diseases
por: Nessler, Stefan
Publicado: (2019)

Commentary: Inside out
por: D'Amico, Thomas A.
Publicado: (2021)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
por: Vryza, Paraskevi, et al.
Publicado: (2023)

A combination microparticle strategy for achieving antigen-specific tolerance
por: Scott, Evan A., et al.
Publicado: (2022)

The need for uniform and coordinated practices involving centrally manufactured cell therapies
por: Stroncek, David, et al.
Publicado: (2022)

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

A model for specific goals for in-patient treatment linked to resources and limitations in out-patient treatment
por: Davies, Virginia
Publicado: (2020)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Urinary prostate specific antigen, usefulness is still a matter of controversy
por: Hekal, Ihab Ahmed
Publicado: (2013)

Reference range of serum prostate-specific antigen levels in Indian men
por: Mittal, Rama Devi
Publicado: (2014)

Checkpoint immunotherapy for NK/T cell lymphoma—Time for a showdown?
por: Chan, Jason Yongsheng, et al.
Publicado: (2021)

Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells
por: Rajasekaran, Kamalakannan, et al.
Publicado: (2022)

Pharmaceutical Manufacturer Prescription Assistance Programs: Are They Worth It?
por: Chen, Judy T., et al.
Publicado: (2007)

Tapping out a mechanical code for T cell triggering
por: Dustin, Michael L., et al.
Publicado: (2016)

Deciphering the biology of IgG4-related disease: specific antigens and disease?
por: Haldar, Debashis, et al.
Publicado: (2018)

No Easy Way Out (Or in)
por: De Weer, Paul
Publicado: (1999)

The INs and OUTs of mitofusins
por: Giacomello, Marta, et al.
Publicado: (2018)

Parkinson’s Inside Out
por: Stamford, Jon, et al.
Publicado: (2016)

Commentary: Out with the flow
por: Errico, Kristen, et al.
Publicado: (2021)

Singing in and out of COVID
por: Phyland, Debra Jean
Publicado: (2022)

Defects in the origin licensing checkpoint stresses cells exiting G0
por: Blow, J. Julian
Publicado: (2019)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
por: Kerepesi, Csaba, et al.
Publicado: (2020)

Misregulated Posttranscriptional Checkpoints: Inflammation and Tumorigenesis
por: Brewer, Gary
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_pl9mtkcr7rbtb7k0kie17n4knq